Lupin Ltd is a high-risk Pharmaceuticals company based in India, specializing in specialty and generic drug manufacturing. With a risk rating score of 32.4, Lupin Ltd focuses on environment, sustainability, and governance (ESG). The company's global formulations business offers a diverse range of branded and generic formulations worldwide, operating primarily in the pharmaceuticals and related products sector. Lupin Ltd also has a strong presence in high-barrier markets like Inhalation, Biosimilars, and Complex Injectables. Their largest sales market is in the United States, followed by India.